CHICAGO – Several patients with acute myeloid leukemia (AML), who were treated with SENTI-202, a first-in-class chimeric antigen receptor natural killer (CAR NK) cell therapy, experienced a complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results